Quarterly results: Avecho; Melodiol; Bioxyne/BLS; Emyria; Ecofibre; Zelira; Elixinol; AusCann; Botanix by Steve Jones and Martin Lane January 31, 2024July 11, 2024 Avecho Biotechnology will begin its low-dose CBD phase III clinical trial in the next two months […]
Financial results: Bod Science; Zelira Therapeutics; Emyria; Epsilon Healthcare; Elixinol; MGC Pharma by Steve Jones August 1, 2023April 30, 2024
Zelira share price rockets as study shows cannabinoid drug outperforms multibillion dollar Pfizer product by Steve Jones June 1, 2023April 30, 2024
Company news: Zelira Therapeutics; Epsilon Healthcare; Creso Pharma by Martin Lane and Steve Jones May 23, 2023April 30, 2024
Company news: Wellnex Life; Creso Pharma; MGC Pharma; Zelira Therapeutics by Martin Lane March 16, 2023April 30, 2024
Financial results: Elixinol; Emyria; Epsilon; Avecho; Creso Pharma; AusCann; MGC Pharma; Botanix; Zelira by Martin Lane and Steve Jones March 1, 2023April 30, 2024
Company news: Delta 9 Cannabis; Little Green Pharma; Zelira Therapeutics; Emyria by Martin Lane and Steve Jones February 16, 2023April 30, 2024
Company news: Neurotech; Emyria; Cann Group; Incannex; Creso Pharma; Greenfern; Zelira; Organic Genetics by Martin Lane November 24, 2022April 29, 2024
Company news: Zelira Therapeutics; Hygrovest; Epsilon Healthcare by Martin Lane September 22, 2022April 29, 2024
Financial results: Avecho; AusCann; Zelira; Elixinol; Cann Group; Incannex; Creso Pharma; Medlab; Rua Bioscience by Steve Jones and Martin Lane September 1, 2022April 29, 2024